Compare iShares Gold Trust (IAU) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Gold Trust vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares Gold Trust trades at $78.78 (market cap $61.51B), while Vertex Pharmaceuticals Incorporated trades at $514.16 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.1× iShares Gold Trust's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, iShares Gold Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Gold Trust for 49 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| IAU | VRTX | |
|---|---|---|
Market Cap | $61.51B | $127.55B |
Volume | 3,206,729 | 1,487,944 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $101.57 | $557.96 |
52-Week Low | $74.21 | $407.37 |
Typical Hold Time | 49 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAU stock trades at $77.06, down 1.67% amid bearish technical signals with 13 of 13 moving averages indicating sell signals. The stock faces pressure from rising Treasury yields and Federal Reserve rate uncertainty, though recent soft inflation data has tempered rate-hike expectations. Support levels cluster around $76-77 while resistance sits at $78.
The outlook remains challenging with technical indicators overwhelmingly bearish and macroeconomic headwinds persisting. However, the RSI_12 reading of 25.07 suggests potential oversold conditions, creating possible tactical opportunities for contrarian investors despite the dominant downward trend.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
